GCG and type 2 diabetes mellitus: A phase II trial by Eli Lily demonstrated that AL can block glucagon signaling in type 2 diabetes, resulting in reduced glucose levels.[37, 38] As shown in Figure 5D,E, glucagon blocked endothelial cell tube formation; however, AL rescued this phenotype.